Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species
Ayumi Fujisawa, Kanagawa (JP); Mayumi Kubomura, Kanagawa (JP); Sakiko Saeki, Tokyo (JP); and Shuji Saito, Kanagawa (JP)
Assigned to CEVA SANTE ANIMALE, Libourne (FR)
Filed by CEVA SANTE ANIMALE, Libourne (FR)
Filed on Aug. 21, 2023, as Appl. No. 18/452,624.
Application 18/452,624 is a continuation of application No. 17/475,385, filed on Sep. 15, 2021, granted, now 11,730,807.
Application 17/475,385 is a continuation of application No. 16/707,106, filed on Dec. 9, 2019, granted, now 11,123,425.
Application 16/707,106 is a continuation of application No. 15/972,283, filed on May 7, 2018, granted, now 10,500,270.
Application 15/972,283 is a continuation of application No. 14/388,268, granted, now 10,251,951, previously published as PCT/EP2013/056839, filed on Mar. 29, 2013.
Claims priority of application No. 12305390 (EP), filed on Mar. 30, 2012.
Prior Publication US 2024/0082390 A1, Mar. 14, 2024
1. A recombinant avian herpes virus of turkeys (HVT), which comprises (i) a first recombinant nucleotide sequence encoding a glycoprotein B (gB) protein of infectious laryngotracheitis virus (ILTV) or an immunogenic fragment thereof, inserted into a non-coding region of the viral genome located between UL45 and UL46, and (ii) a second recombinant nucleotide sequence encoding an antigenic peptide, distinct from an antigenic peptide of infectious laryngotracheitis virus (ILTV), wherein said second recombinant nucleotide sequence is inserted into a non-coding region of the viral genome chosen among the region located between UL44 and UL45, the region located between US10 and SORF3, and the region located between SORF3 and US2.